Chennai Journal

Cold Agglutinin Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Cold Agglutinin Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 02
18:45 2021
Cold Agglutinin Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
“Cold Agglutinin Disease (CAD) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cold Agglutinin Disease (CAD) market. A detailed picture of the Cold Agglutinin Disease (CAD) pipeline landscape is provided, which includes the disease overview and Cold Agglutinin Disease (CAD) treatment guidelines.

DelveInsight’s Cold Agglutinin Disease Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Cold Agglutinin Disease pipeline landscapes. It comprises Cold Agglutinin Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cold Agglutinin Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cold Agglutinin Disease pipeline products.     

Some of the key takeaways of the Cold Agglutinin Disease Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Sanofi, Apellis Pharmaceuticals, Janssen Pharmaceutical, etc., are developing therapies for the treatment of Cold Agglutinin Disease.

  • Emerging therapies such as Sutimlimab, APL-2, Bortezomib, are expected to have a significant impact on the  Cold Agglutinin Disease market in the coming years.

  • Currently, Sanofi is conducting the Phase III clinical trial of Sutimlimab for CAD and met the primary endpoints and secondary endpoints and demonstrated rapid inhibition of hemolysis. 

  • Apellis is currently testing APL-2 in Phase II and assessing the safety, tolerability, efficacy, and PK of multiple subcutaneous doses of APL-2. 

Get an overview of pipeline landscape @ Cold Agglutinin Disease Clinical Trials Analysis 

Cold agglutinin disease is an uncommon autoimmune hemolytic anaemia in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. 

Cold Agglutinin Disease Emerging Drugs

  • Sutimlimab by Sanofi

  • APL-2 by Apellis Pharmaceuticals

  • Bortezomib by Janssen Pharmaceutical

Scope of Cold Agglutinin Disease Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Sanofi, Apellis Pharmaceuticals, Janssen Pharmaceutical, and others.

  • Pipeline Therapies: Sutimlimab, APL-2, Bortezomib, and others.

Table of Contents

1

Cold Agglutinin Disease Report Introduction

2

Cold Agglutinin Disease Executive Summary

3

Cold Agglutinin Disease Overview

4

Cold Agglutinin Disease- Analytical Perspective In-depth Commercial Assessment

5

Cold Agglutinin Disease Pipeline Therapeutics

6

Cold Agglutinin Disease Late Stage Products (Phase II/III)

7

Cold Agglutinin Disease Mid Stage Products (Phase II)

8

Cold Agglutinin Disease Early Stage Products (Phase I)

9

Cold Agglutinin Disease Preclinical Stage Products

10

Cold Agglutinin Disease Therapeutics Assessment

11

Cold Agglutinin Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Cold Agglutinin Disease Key Companies

14

Cold Agglutinin Disease Key Products

15

Cold Agglutinin Disease Unmet Needs

16 

Cold Agglutinin Disease Market Drivers and Barriers

17

Cold Agglutinin Disease Future Perspectives and Conclusion

18

Cold Agglutinin Disease Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Cold Agglutinin Disease Market

DelveInsight’s Cold Agglutinin Disease – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cold Agglutinin Disease Epidemiology

DelveInsight’s Cold Agglutinin Disease – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Cold Agglutinin Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles